Cryoport, INC 10-Q quarterly reports

Cryoport, Inc. announced its Q2 2026 results, showcasing revenue growth driven by its Life Sciences Services segment, while also detailing the impact of its CRYOPDP business divestiture.

Cryoport, Inc. announced its first quarter 2026 financial results, showcasing a 16.5% increase in total revenue driven by strong performance in both its Life Sciences Services and Life Sciences Products segments.

Cryoport, Inc. reported a 15.4% increase in total revenue for the third quarter of 2025, driven by strong demand in life sciences services and products, alongside a significant gain from the divestiture of its CRYOPDP business.

Cryoport, Inc. reports a significant swing to net income in Q2 2025, driven by the strategic divestiture of its CRYOPDP business and strong growth in core life sciences services.

Cryoport, Inc. announces its Q1 2025 financial results, including revenue growth and a strategic decision to divest its CRYOPDP business to DHL.

Cryoport's Q3 2024 results show a slight revenue increase, offset by a significant impairment charge and strategic debt repurchases.

Cryoport's Q2 2024 results show a net loss due to a significant goodwill impairment, despite a slight increase in overall revenue.

Cryoport's Q1 2024 results show a decrease in total revenue, primarily due to lower product sales, while the company continues to invest in strategic growth initiatives.